CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemiaAlessandro Cafaro, Claudio Cerchione, Carla Masini et al.|Minerva Medica|2020Cited by 13
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactionsAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Mouna Jandoubi et al.|Journal of Translational Medicine|2024Cited by 5